Clinical Study on Resolving Toxin Ultrafine Powder( 化毒超微粉) in the Treatment of 30 Cases of Persistent High-Risk Human Papilloma Virus Infection in Women with Damp Toxin Stagnation Syndrome
|更新时间:2021-11-10
|
Clinical Study on Resolving Toxin Ultrafine Powder( 化毒超微粉) in the Treatment of 30 Cases of Persistent High-Risk Human Papilloma Virus Infection in Women with Damp Toxin Stagnation Syndrome
Journal of Traditional Chinese MedicineVol. 61, Issue 4, Pages: 325-329(2020)
WANG Zhuanhong, LI Jun, ZHAO Lingling, et al. Clinical Study on Resolving Toxin Ultrafine Powder( 化毒超微粉) in the Treatment of 30 Cases of Persistent High-Risk Human Papilloma Virus Infection in Women with Damp Toxin Stagnation Syndrome[J]. Journal of Traditional Chinese Medicine2020, 61(4): 325-329.
WANG Zhuanhong, LI Jun, ZHAO Lingling, et al. Clinical Study on Resolving Toxin Ultrafine Powder( 化毒超微粉) in the Treatment of 30 Cases of Persistent High-Risk Human Papilloma Virus Infection in Women with Damp Toxin Stagnation Syndrome[J]. Journal of Traditional Chinese Medicine2020, 61(4): 325-329.DOI: 10.13288/j.11-2166/r.2020.04.012.
Clinical Study on Resolving Toxin Ultrafine Powder( 化毒超微粉) in the Treatment of 30 Cases of Persistent High-Risk Human Papilloma Virus Infection in Women with Damp Toxin Stagnation Syndrome
Objective To observe the clinical efficacy and safety of Resolving Toxin Ultrafine Powder(化毒超微粉) for the treatment of low-reproductive tract high-risk human papilloma virus(HR-HPV) infection in women with damp toxin stagnation syndrome. Methods A total of 60 female patients with persistent HR-HPV infection of damp toxin stagnation syndrome were randomly divided into a treatment group and a control group
with 30 cases in each group. The treatment group was given Resolving Toxin Ultrafine Powder vaginal spray
3 g each time. The control group was given 1 vaginal effervescent capsule of recombinant human interferon a2 b to the vagina. Both groups were treated once every other day
10 times for a course of treatment. The drug was discontinued during menstruation
and 3 consecutive courses of treatment were used. Twelve months after the end of treatment(after treatment)
the HR-HPV negative rate
the efficacy of traditional Chinese medicine(TCM) syndromes
the clinical efficacy
and the occurrence of adverse reactions were observed in both groups of patients. The total scores of TCM syndromes and the Reid colposcope score(RCI) were compared before and after treatment. Results After treatment
the HR-HPV negative rate in the treatment group was 83.33%
which was significantly higher than the control group′s 60.00%(P=0.045). TCM syndrome effective rate of the treatment group was 96.70%
which was significantly higher than that of the control group(50.00%
P<0.05); the total effective rate of clinical efficacy in the treatment group was 86.7%
which was significantly higher than the 63.3% in the control group(P<0.05). The TCM syndrome scores and RCI total scores after treatment were decreased compared with those before treatment in the 2 groups
and the decline was more significant in the treatment group(P<0.01). No adverse reactions occurred during the treatment in both groups. Conclusions Resolving Toxin Ultrafine Powder can effectively clear the female genital tract HR-HPV infection
Syndrome Differentiation and Treatment of Cholinergic Urticaria from the Perspective of "Treating Fire Constraint by Dispersing It"
Effect of Xiaoqinglong Decoction (小青龙汤) on Th2 Immune Responses and Nasal Mucosal TSLP/OX40L Pathway in Allergic Rhinitis Model Rats
Exploring the Comorbidity Mechanism,Prevention and Treatment Strategies of Rheumatoid Arthritis with Coronary Atherosclerotic Heart Disease Based on Collateral Disease Theory
A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind
Construction and Application of "Source-Pivot-Convergence" Pattern Identification and Treatment Model for Malignant Tumors